Assorted programs"We are evaluating the data obtained to date and considering our plans for the treatment of NMOSD using an AIM Biologicals platform."
"We are currently continuing in-vitro and in-vivo testing of antigen-specific AIM Biologics candidate molecules for the potential treatment of Parkinson’s disease."
"The company is evaluating the next steps for PGX-YBG for ILD. If the company decides to progress it to clinical trial as a potential inhalable immune-therapeutic treatment for severe forms of ILD which may include IPF and COVID-19 related lung fibrosis, we would first be required to undertake and obtain results from IND enabling toxicology studies before."
"Through research we are funding at The University of Queensland, we have been conducting pre-clinical experiments to seek to identify a potential alternative formulation suitable for use in ALS patients, the results of which we are currently evaluating."